Mxi1-SRalpha: a novel Mxi1 isoform with enhanced transcriptional repression potential.

Oncogene

Department of Molecular Genetics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann 809, Bronx, New York 10461, USA.

Published: November 2004

Mxi1 belongs to the Myc/Max/Mad network of proteins that have been implicated in the control of multiple aspects of cellular behavior. Previously, we had reported that the mouse mxi1 gene gives rise to two distinct transcript forms that can encode proteins with dramatically different functional abilities. The Mxi1-SR protein (here termed Mxi1-SRbeta) can interact with Sin3/histone deacetylase and function as a potent transcriptional repressor and growth suppressor, while the Mxi1-WR protein lacks these activities. Here, we describe a new mxi1-derived transcript form (termed mxi1-SRalpha) whose expression is governed by its own promoter, resulting in a spatiotemporally distinct expression profile from that of the highly related mxi1-SRbeta form. Moreover, the Mxi1-SRalpha protein product, with its unique Sin3 interacting domain, has a greater affinity than its Mxi1-SRbeta counterpart for the Sin3 adapter proteins as well as an enhanced potential for transcriptional repression in transient reporter assays. Our identification of this novel Mxi1 isoform that results from alternative 5' exon usage adds an additional layer of complexity to the Mad/Mxi1 family. In addition, our findings warrant re-evaluation of mxi1 expression patterns on the cellular level and its status in human cancer samples, with a renewed focus on the distinct isoforms.

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1208107DOI Listing

Publication Analysis

Top Keywords

novel mxi1
8
mxi1 isoform
8
transcriptional repression
8
mxi1
5
mxi1-sralpha novel
4
isoform enhanced
4
enhanced transcriptional
4
repression potential
4
potential mxi1
4
mxi1 belongs
4

Similar Publications

Article Synopsis
  • Tumor-associated macrophages (TAMs) play crucial roles in glioma progression and immune response, but their interactions in different glioma types, particularly IDH-WT, are not fully understood, affecting clinical trial outcomes.
  • Our research highlighted two specific TAM subsets linked to poor patient survival and ineffective response to anti-PD-1 therapy in IDH-WT glioblastoma, suggesting the SLAMF9 receptor as a potential treatment target.
  • We identified key gene interactions and transcription factors related to TAMs that contribute to tumor growth and immunosuppression, with consistent expression patterns observed even between primary and recurrent tumors, indicating stable networks for therapeutic strategies in IDH-WT GBM.
View Article and Find Full Text PDF

Aims: NUTM1-rearranged sarcoma is an emerging entity that differs from NUT carcinoma at the molecular level, with most of the former tumours harbouring fusions involving genes in the MYC-associated factor X dimerization (MAD) transcription family (MXD1, MXD4, MXI1 [or MXD2], and MGA). MGA::NUTM1 is one of the most recently described novel gene fusions associated with NUTM1-rearranged sarcoma. Herein we describe the clinicopathologic features of three sarcomas with an MGA::NUTM1 fusion.

View Article and Find Full Text PDF

ADD3 Deletion in Glioblastoma Predicts Disease Status and Survival.

Front Oncol

December 2021

Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong SAR, China.

Loss of heterozygosity (LOH) on chromosome 10 frequently occurs in gliomas. Whereas genetic loci with allelic deletion often implicate tumor suppressor genes, a putative tumor suppressor Adducin3 () mapped to chromosome 10q25.2 was found to be preferentially downregulated in high-grade gliomas compared with low-grade lesions.

View Article and Find Full Text PDF

An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Breast Cancer.

Int J Womens Health

November 2021

Departments of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China.

Background: Aging, an inevitable process characterized by functional decline over time, is a significant risk factor for various tumors. However, little is known about aging-related genes (ARGs) in breast cancer (BC). We aimed to explore the potential prognostic role of ARGs and to develop an ARG-based prognosis signature for BC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!